GHK-Cu peptide claims: what the science actually supports

What did @just_jessv actually say?

She said GHK-Cu, which she calls "GHQ" throughout, is the peptide she misses most while paused before surgery. Not because of its well-known skin or hair effects, but because it completely eliminated her chronic lower back pain. She described years of unresolved back pain, a history as a gymnast, a snowboarding fall she suspects caused bone or nerve damage, and said "when I take it I have no pain at all." She also acknowledged nobody has diagnosed the underlying cause. She directed viewers to a provider linked in her bio, noting GHK-Cu is only visible after account registration.

To her credit, she disclosed she is not a doctor, does not sell the peptide, and was transparent that she does not know her own diagnosis. That context matters when reading everything else she said.

Does the science back this up?

Partially, but the jump from lab findings to "no pain at all" in humans is a significant leap. GHK-Cu is one of the more researched peptides in the cosmetic and wound-healing literature, but systemic pain relief in humans is not an established clinical outcome.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has demonstrated real effects in preclinical settings. Pickart and Margolina (2018, Symmetry) reviewed evidence showing GHK-Cu upregulates genes involved in tissue repair, anti-inflammation, and nerve regeneration in cell and animal models. Separately, Pickart et al. (2012, Journal of Biomaterials Science) showed fibroblast activation and collagen synthesis in wound models, which is the mechanism she references. These findings are real. The problem is that cell culture results and rodent data do not translate automatically to a human injecting subcutaneously for back pain of unknown origin. There are no published randomized controlled trials in humans testing GHK-Cu for musculoskeletal pain. Her personal outcome, whatever caused it, is not evidence the peptide is doing what she thinks it is doing.

What did they get wrong (or right)?

She got the basic mechanism roughly right and got several other things wrong or oversimplified.

• Right: GHK-Cu does activate fibroblasts and has legitimate evidence for tissue repair signaling in preclinical studies. Calling it more than a "skin peptide" is defensible in that the research covers wound healing, nerve tissue, and inflammation modulation beyond cosmetics.
• Mostly right: Hair regrowth evidence exists. Kang et al. (2014, Archives of Dermatological Research) found GHK-Cu promoted hair follicle enlargement and proliferation in animal models. Human evidence remains thin but is not zero.
• Wrong: Describing her back pain relief as something GHK-Cu is definitively causing is a causal claim she cannot support. She has an undiagnosed condition. She stopped and restarted other peptides simultaneously. Placebo response for chronic pain is well-documented and can be substantial in motivated patients. Without a controlled comparison, this is anecdote, not evidence.
• Wrong by omission: She never mentions that subcutaneous GHK-Cu is a compounded peptide without FDA approval for any systemic therapeutic use, or that quality and dosing consistency across compounding pharmacies varies significantly.

What should you actually know?

GHK-Cu has a more serious research base than most influencer-promoted peptides, but serious is not the same as proven for the use case she is describing.

The peptide was first isolated from human plasma in 1973 by Loren Pickart. Most of the mechanistic research since then is from the same research group or from cosmetic applications. That is a real limitation. Independent replication in human clinical trials for systemic effects, especially pain or musculoskeletal repair, does not exist in any meaningful volume. If you have chronic back pain of unknown origin, a TikTok creator's anecdote about a compounded injectable peptide is not a treatment plan. Her experience might be genuine. It might be placebo. It might be that stopping other peptides or her pre-surgery changes in activity level affected her pain. There is no way to know from what she shared.

The referral pathway she describes, creating an account to access an unlisted product through her provider link, is also worth noting. That structure is not inherently illegal for telehealth peptide providers, but it should prompt questions about prescribing oversight, lab sourcing, and whether a clinician is actually reviewing your individual history before dispensing.

The bottom line on GHK-Cu

This is a peptide with real preclinical science behind it and almost no human clinical trial data for systemic use. The skin and hair applications have the strongest (though still limited) evidence base. The back pain claim is a personal anecdote attached to an undiagnosed condition, which is not a foundation for anyone else's medical decision. GHK-Cu is not approved by the FDA for any therapeutic use. It is available through compounding pharmacies under prescriber oversight in the US, but compounded does not mean standardized, and "my provider" linked in a bio is not a substitute for evaluation by someone who knows your history.